P2‐550: Plasma Measures of Inflammation Associated With Clinical Progression and Cognitive Decline During Preclinical Ad
Year: 2019
Type: article
Study design: Observational Study
Abstract: Inflammatory responses have been implicated in Alzheimer's disease (AD) pathophysiological processes. Few studies have also evaluated the risk of non-inflammatory markers of immune functioning (i.e., innate immune activation and adaptive immunity). In this study, we examined the prospective association between blood biomarkers of immune activation in cognitively normal individuals and subsequent cognitive decline and clinical progression to mild cognitive impairment (MCI). Plasma was collected from cognitively normal participants (N=191; mean age 65.2 years; mean follow-up 5.8 years). Specimens were assayed for markers of chronic inflammation (TNFR1, IL-6), adaptive immunity (CD25, a marker of T-cell activity), and innate immune activation (CD14 and CD163). Survival analysis was used to evaluate the association of each blood marker, as well as an inflammatory index comprised of TNFR1 and IL-6, with time to progression to MCI. Latent growth curve modeling, with age as the timescale and random effects for person and time, was used to model changes in cognition for each blood marker. Higher levels of plasma TNFR1 were associated with greater risk of progression from normal cognition to MCI (HR: 3.27; 95% confidence interval, CI: 1.27, 8.40) (Table 1). Elevated levels of TNFR1 were also associated with steeper rate of general cognitive decline on follow-up (Table 2). IL-6 and non-inflammatory markers of innate and adaptive immune activation were not associated with clinical progression or cognitive decline.
Source: Alzheimer s & Dementia
Institutions: Johns Hopkins University, Johns Hopkins Medicine
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2980463587